NDC 0264-4850 Propofol Lipuro

Propofol Lipuro

NDC Product Code 0264-4850

NDC 0264-4850-01

Package Description: 10 VIAL in 1 CARTON > 100 mL in 1 VIAL

NDC Product Information

Propofol Lipuro with NDC 0264-4850 is a a human prescription drug product labeled by B. Braun Medical Inc.. The generic name of Propofol Lipuro is propofol lipuro. The product's dosage form is injection, emulsion and is administered via intravenous form.

Labeler Name: B. Braun Medical Inc.

Dosage Form: Injection, Emulsion - An emulsion consisting of a sterile, pyrogen-free preparation intended to be administered parenterally.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Propofol Lipuro Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • PROPOFOL 10 mg/mL

Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)
  • SODIUM OLEATE (UNII: 399SL044HN)
  • WATER (UNII: 059QF0KO0R)
  • SOYBEAN OIL (UNII: 241ATL177A)
  • GLYCERIN (UNII: PDC6A3C0OX)
  • EGG PHOSPHOLIPIDS (UNII: 1Z74184RGV)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • General Anesthesia - [PE] (Physiologic Effect)
  • General Anesthetic - [EPC] (Established Pharmacologic Class)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: B. Braun Medical Inc.
Labeler Code: 0264
Marketing Category: UNAPPROVED DRUG OTHER - What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 03-12-2021 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2022 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Propofol Lipuro Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Fact Sheet For Health Care Providers

  • EMERGENCY USE AUTHORIZATION (EUA) OF PROPOFOL-LIPURO 1%INJECTABLE EMULSION FOR INFUSIONThe U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of the unapproved product, Propofol-Lipuro 1% injectable emulsion for infusion in 100 mL to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an intensive care unit (ICU) setting. Propofol-Lipuro 1% injectable emulsion for infusion is not an FDA-approved drug in the United States. However, FDA has issued an EUA permitting the emergency use of Propofol-Lipuro 1% injectable emulsion for infusion during the COVID-19 pandemic and related shortage of propofol drug product.Propofol-Lipuro 1% injectable emulsion for infusion is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3-(b)(1), unless the authorization is terminated or revoked sooner.The scope of the EUA is limited as follows:Propofol-Lipuro 1% injectable emulsion for infusion will be used only to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation.Propofol-Lipuro 1% injectable emulsion for infusion will be administered only by a licensed healthcare provider in an ICU setting.Propofol-Lipuro 1% injectable emulsion for infusion will NOT be administered to pregnant women, unless there are no FDA-approved products available to maintain sedation for these patients should they require mechanical ventilation in an ICU setting.Propofol-Lipuro 1% injectable emulsion for infusion will be used only in accordance with the dosing regimens as detailed in the authorized Fact Sheets.Product DescriptionConsistent with the EUA, B. Braun Melsungen AG, Germany, will offer the following presentations of Propofol-Lipuro 1% Emulsion. Product Name And DescriptionMCT/LCT ConcentrationSource/Type of OilSize National Drug Code (NDC) Propofol-Lipuro 1 % injectable emulsion for infusion 1,000 mg in 100 mL (propofol 10 mg per mL)Medium Chain Triglycerides (MCT) 50 mg/mL  Long Chain Triglycerides (LCT) 50 mg/mLSoybean oil, refined; medium-chain triglycerides 100 mLNDC 0264-4850-01Propofol-Lipuro 1% injectable emulsion for infusion is approved in Europe as well as in many other international countries.Propofol-Lipuro 1% injectable emulsion for infusion will be manufactured by B. Braun facilities in Germany as Propofol-Lipuro 1% Emulsion supplied in all other countries worldwide. The B. Braun’s manufacturing sites are inspected regularly by German and other National Competent Authorities confirming the fulfillment of good manufacturing practices (GMP) and other current standards. The manufacturing site in Melsungen, Germany was previously inspected by FDA.Key Differences between FDA-approved Diprivan (propofol) Injectable Emulsion, USP Products and Propofol-Lipuro 1% (Propofol) injectable emulsion for infusion  Diprivan (propofol) Injectable Emulsion, USP Propofol 1,000 mg per 100 mL (10 mg per mL)Propofol-Lipuro 1%(propofol) injectable emulsion for infusion 1,000 mg in 100 mL (10 mg/mL) What does this mean to you as a healthcare professional?Composition Contains long-chain triglycerides (LCT)Contains a combination of medium-chain triglycerides (MCT) and long-chain triglycerides (LCT)Prolonged IV infusion of MCT to pregnant rabbits has been reported in the published literature to increase the RISK OF NEURAL TUBE DEFFECTS.Because it is not yet clear if there is differential risk for adverse developmental effects with Propofol-Lipuro 1% compared to Diprivan (propofol), Propofol-Lipuro 1% SHOULD NOT BE USED IN PREGNANT WOMEN unless there are no FDA-approved products available to maintain sedation in these patients who require mechanical ventilation in an ICU setting.IndicationGeneral anesthesia, procedural sedation, ICU sedationICU sedation ONLYPropofol-Lipuro 1% is only to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in the ICU setting.Patient Population Greater than 3 years old (procedural sedation and general anesthesia) Greater than 16 years old (ICU sedation)Greater than 16 years old (ICU sedation)Propofol-Lipuro 1% is only indicated to maintain sedation via continuous infusion for patients greater than 16 years old who require mechanical ventilation in the ICU setting.Propofol-Lipuro 1% should not be used in pregnant women unless there are no FDA-approved products available to maintain sedation for these patients who require mechanical ventilation in an ICU setting. DosingSee package insert*Administration rates of 0.3 to 4.0 mg propofol/kg bodyweight/h have been demonstrated to provide adequate sedationInfusion rates greater than 4.0 mg propofol/kg bodyweight/h are not recommended due to risk of Propofol Infusion Syndrome.The duration of administration must not exceed 7 days.Method of AdministrationBolus or infusion Infusion ONLYPropofol-Lipuro 1% should be administered undiluted intravenously by continuous infusion. DO NOT ADMINISTER PROPOFOL-LIPURO 1% VIA BOLUS INJECTION.Containers should be shaken before use. If two layers can be seen after shaking, the emulsion should not be used.Do not admix with other medicinal products. Co-administration of other medicinal products or fluids added to the Propofol-Lipuro 1% infusion line must occur close to the cannula site using a Y-piece connector or a three-way valve. Propofol-Lipuro 1% Emulsion must not be administered via a microbiological filter.Other Special Patient PopulationsSee package insert* Caution should be taken when treating patients with mitochondrial disease, epilepsy, and disorders of fat metabolism. Patients with mitochondrial disease may be susceptible to exacerbations of their disorder when undergoing ICU care. Maintenance of normothermia, provision of carbohydrates and good hydration are recommended for such patients. The early presentations of mitochondrial disease exacerbation and of the ‘propofol infusion syndrome’ may be similar.Although several studies have demonstrated efficacy in treating status epilepticus, administration of propofol in epileptic patients may also increase the risk of seizure. For these patients, as well as for ARDS/respiratory failure and tetanus patients, sedation maintenance dosages were generally higher than those for other critically ill patient populations.Appropriate care should be applied in patients with disorders of fat metabolism and in other conditions where lipid emulsions must be used cautiously. It is recommended that blood lipid levels should be monitored if propofol is administered to patients thought to be at particular risk of fat overload. Administration of propofol should be adjusted appropriately if the monitoring indicates that fat is being inadequately cleared from the body. If the patient is receiving other intravenous lipid concurrently, a reduction in quantity should be made in order to take account of the amount of lipid infused as part of the propofol formulation; 1.0 mL of Propofol-Lipuro 1 % Emulsion contains approximately 0.1 g of fat. Drug interactionSee package insert* Drug interaction with rifampicin, valproate Profound hypotension has been reported following anesthetic induction with propofol in patients treated with rifampicin.A need for lower propofol doses has been observed in patients taking valproate. When used concomitantly, a dose reduction of propofol may be considered.Presence of antimicrobial retardant Yes NOPropofol-Lipuro 1 % does NOT contain an antimicrobial retardant and supports growth of microorganisms.STRICT ASEPTIC TECHNIQUE MUST ALWAYS BE MAINTAINED DURING HANDLING.Each vial of Propofol-Lipuro 1 % is intended only for single administration for an individual patient. Vials are not intended for multiple use. Propofol-Lipuro 1% must be drawn up aseptically into a sterile syringe or an infusion set immediately after breaking the vial seal. Administration must commence without delay. Asepsis must be maintained for both Propofol-Lipuro 1 % Emulsion and the infusion equipment throughout the infusion period.The unused portion of a vial should be discarded immediately after opening. As with any propofol used in infusion,discard all product and infusion lines after 12 hours. ContraindicationsSee package insert* Propofol-Lipuro 1 % Emulsion should not be used in patients who are hypersensitive to peanut or soyPropofol-Lipuro 1 % is contraindicated in patients with a known hypersensitivity to the active substance or to any of the excipients:  soybean oil, refined; medium-chain triglycerides; glycerol; egg lecithin; sodium oleate; water for injections.Propofol-Lipuro 1 % contains soya-bean oil and should not be used in patients who are hypersensitive to peanut or soy. Bar codeUnit of use barcode on individual vialsNo unit of use barcodeThe barcode on the imported product label may not register accurately with the U.S. scanning systems. Institutions should manually input the imported product information into their systems and confirm that the barcode, if scanned, provides correct information. Alternative procedures should be followed to assure that the correct drug product is being used and administered to individual patients.  *Refer to https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/019627s066lbl.pdf for the Diprivan package insert.Please refer to the package insert for the full prescribing information of Propofol-Lipuro 1% injectable emulsion for infusion.For questions regarding Propofol-Lipuro 1% injectable emulsion for infusion, please contact B. Braun Medical Inc.:Company Name:          B. Braun Medical Inc.Address:                       861 Marcon Blvd, Allentown, PA 18109Country:                       United States24-hour Telephone:     +1 833-425-1464E-Mail:                           productqualityexcellence@bbraunusa.comWhat is an EUAThe United States FDA has made Propofol-Lipuro 1% injectable emulsion for infusion available to treat patients in an ICU during the COVID-19 pandemic under an emergency access mechanism called an Emergency Use Authorization (EUA). This EUA is supported by a Secretary of Health and Human Service (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic. Propofol-Lipuro 1% injectable emulsion for infusion made available under an EUA has not undergone the same type of review as an FDA-approved product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives. Based on the totality of scientific evidence available, it is reasonable to believe that Propofol-Lipuro 1% injectable emulsion for infusion has met certain criteria for safety, performance, and labeling and may be effective to maintain sedation via continuous infusion in patients greater than 16 years old who require mechanical ventilation in an ICU setting.This EUA for Propofol-Lipuro 1% injectable emulsion for infusion is in effect for the duration of the COVID-19 declaration justifying emergency use of the product, unless terminated or revoked. The EUA will end when the declaration is terminated or revoked or when there is a change in the approval status of the product such that an EUA is no longer needed. This communication and product information is available on the B. Braun Medical Inc. website https://www.bbraunusa.com/en/company/newsroom/covid19.html# as well as the FDA webpage which includes links to patient fact sheet.Adverse Event ReportingHealthcare facilities and prescribing healthcare providers or their designee receiving Propofol-Lipuro 1 % injectable emulsion for infusion will track all medication errors associated with the use of and all serious adverse events that are considered potentially attributable to Propofol-Lipuro 1% injectable emulsion for infusion.  Adverse events or quality problems experienced with the use of this product must also be reported to the FDA using one of the following methods:Complete and submit a MedWatch form online: www.fda.gov/medwatch/report.htm orComplete and submit FDA Form 3500 (health professional) by fax (1-800-FDA-0178) (this form can be found via link above).Call 1-800-FDA-1088 for questions.  Submitted reports should state, “Propofol-Lipuro 1% injectable emulsion for infusion use for COVID-19 under Emergency Use Authorization (EUA)” at the beginning of the question “Describe Event” for further analysis.For questions regarding Propofol-Lipuro 1% (10 mg/mL) injectable emulsion for infusion for continuous infusion, please contact B. Braun Medical Inc.:Company Name:           B. Braun Medical Inc.24-hour Telephone:     +1 833-425-1464E-Mail:                           productqualityexcellence@bbraunusa.comComparison Table of FDA-approved Diprivan (propofol) Injectable Emulsion, USP 10 mg/mL and Propofol-Lipuro 1 % (10 mg/mL) injectable emulsion for infusion Product Name Diprivan (propofol) Injectable Emulsion, USPPropofol-Lipuro 1 % injectable emulsion for infusion Propofol concentration 10 mg/mL 10 mg/mLProduct labels 100 mL  Note: The imported product labels include that Propofol-Lipuro 1% is “for injection or infusion”. However, Propofol-Lipuro 1% is only authorized for use in the U.S. as “for infusion”.  Active IngredientPropofolPropofol  ExcipientsSoybean oilGlycerolEgg phospholipidsEdetate disodiumSodium hydroxideSoybean oil, refinedMedium-chain triglyceridesEgg phospholipids for injectionGlycerolSodium oleateWater for injection  Fill Volume20 mL50 mL 100 mL100 mL DurationDrug holiday after 5 days to replace urine zinc lossesDo not administer for more than 7 days. Dilution  Dilution to 2 mg/mL with 5% Dextrose Injection onlyDo Not Dilute. BolusBolus injection permittedInfusion ONLY DescriptionSingle Dose Vial for Single Patient Use OnlySingle Dose Vial for Single Patient Use Only CompanyFresenius Kabi USAB. Braun Melsungen AG GermanyPropofol-Lipuro 1% (propofol)injectable emulsion for infusion1,000 mg in 100 mL (10 mg/mL)Propofol-Lipuro 1% (propofol) injectable emulsion for infusion 1,000 mg in 100 mL (10 mg/mL) contains the same active ingredient, strength, and concentration as Diprivan® (propofol) injectable emulsion for infusion USP 1,000 mg per 100 mL (10 mg per mL).Propofol-Lipuro 1% injectable emulsion for infusion is not FDA-approvedPropofol-Lipuro 1% injectable emulsion for infusion is approved in Europe, as well as many other international countries outside of the United States. Propofol-Lipuro 1% injectable emulsion for infusion has been authorized by FDA for use under an Emergency Use Authorization (EUA)Propofol-Lipuro 1% injectable emulsion for infusion is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3-(b)(1), unless the authorization is terminated or revoked soonerTo place an order, contact your local sales representative.

Fact Sheet For Patients, Parents, And Caregivers

  • Emergency Use Authorization (EUA) of PROPOFOL-LIPURO 1% (propofol) INJECTABLE EMULSION FOR INFUSION During CORONAVIRUS DISEASE 2019 (COVID-19) PandemicThis fact sheet contains information to help you understand the risks and benefits of Propofol-Lipuro 1% (10 mg/mL) injectable emulsion for infusion that you have received or may receive. There is currently a shortage of U.S. Food and Drug Administration (FDA)-approved propofol products that maintain sedation for patients who are on a machine that helps with breathing (ventilator) due to the COVID-19 pandemic. Propofol-Lipuro 1% injectable emulsion for infusion is not an FDA-approved medicine in the United States. Propofol-Lipuro 1%injectable emulsion for infusion contains the same active ingredient, propofol, at the same strength as Diprivan Injectable Emulsion and other propofol products approved in the United States. Propofol-Lipuro 1% injectable emulsion for infusion is currently approved in Europe and other international countries. Read this Fact Sheet for information about Propofol-Lipuro 1% injectable emulsion for infusion. Talk to your healthcare provider if you have questions. It is your choice to take Propofol-Lipuro 1% injectable emulsion for infusion or stop it at any time.What is COVID-19?COVID-19 is caused by a virus called a coronavirus. This type of coronavirus has not been seen before. This new coronavirus was first found in people in December 2019. You can get COVID-19 through contact with another person who has the virus.COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause some of your other medical conditions to become worse. Older people and people of all ages with severe, long lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalized for COVID-19.The symptoms of COVID-19 are fever, cough and shortness of breath, which may appear 2 to 14 days after exposure. Serious illness including breathing problems can occur and may cause your other medical conditions to become worse.What is PROPOFOL-LIPURO 1% INJECTABLE EMULSION FOR INFUSION? Propofol-Lipuro 1% injectable emulsion for infusion belongs to a group of medicines called sedatives/hypnotics. It will be used to help calm (sedate) you if you need a tube inserted (intubation) and a machine to help you breathe (ventilator) while in an ICU. What do I need to know before I receive PROPOFOL-LIPURO 1% INJECTABLE EMULSION FOR INFUSION?Who should not receive Propofol-Lipuro 1% injectable emulsion for infusion?Do not receive Propofol-Lipuro 1% injectable emulsion for infusion if:You have received propofol before and have had an allergic reaction to itYou are allergic (hypersensitive) to soy, peanut, or any of the other ingredients of this medicineYou are 16 years of age or youngerWhat should I tell my healthcare provider before I receive Propofol-Lipuro 1% injectable emulsion for infusion? Please tell your healthcare provider about all of your medical conditions, including if you have:Serious head injuriesMitochondrial diseaseA disorder in which your body does not handle fat properly or any other health problems in which giving you fat emulsions may cause a health problemDehydration (your blood volume is too low, or hypovolemia)Heart, kidney, or liver problemsHigh pressure within your brainProblems with your breathingEpilepsyAre pregnant or plan to become pregnant. Are breastfeeding or plan to breastfeedAre taking any medicines, including prescription, over-the-counter, vitamins, or herbal productsYour healthcare provider will consider that other medicines with an inhibiting effect on the central nervous system may increase the effects of propofol when given together with propofol. Special care will be taken if you are also receiving an antibiotic containing rifampicin or an anti-seizure medication containing valproate.How will I receive PROPOFOL-LIPURO 1% INJECTABLE EMULSION FOR INFUSION? Propofol-Lipuro 1% injectable emulsion for infusion is given to you through a vein (IV) under the direct supervision of an anesthesiologist or intensive care doctor who will closely control the amount of Propofol-Lipuro 1% injectable emulsion given to you.DosageThe dose you are given will vary depending on your age, body weight, and physical condition. The doctor will give the correct dose to achieve the required level of sedation, by carefully watching your responses and vital signs (pulse, blood pressure, breathing, etc). Propofol-Lipuro 1% injectable emulsion will be given by infusion and only for a maximum of 7 days.What are the important possible side effects of PROPOFOL-LIPURO 1% INJECTABLE EMULSION FOR INFUSION?The most common side effects are:Pain at the injection siteDrop in blood pressureChanges in heart rateChanges in breathing, coughing, and hiccupsHeadache, nausea, or vomiting during recovery from propofol sedationLess common side effects are:Blood clots in veins or inflammation of veins at the injection siteSeizuresAllergic reactions, which can include swelling of the face, tongue and/or throat, wheezing and/or difficulty breathing, skin redness, and low blood pressureFluid on lungs (lung edema)Inflammation of the pancreasLoss of sexual control during the time of recoveryChange in color of your urine afterSkin or tissue damage if the medicine is accidentally injected outside of a veinInvoluntary movementsMood changesDrug abuse and drug dependenceHeart failureShallow breathingPain and/or swelling at the injection site after the medicine was accidentally injected outside of a veinWhat other treatment choices are there? Your anesthesiologist or intensive care doctor may give you other sedation agents depending on your medical condition.What if I am pregnant or breastfeeding?Tell your healthcare provider if you are pregnant, think you may be pregnant, or are planning to have a baby. Propofol-Lipuro 1% injectable emulsion for infusionmay harm your unborn baby. Propofol-Lipuro 1% injectable emulsion for infusion should be used in pregnant women only if there are no other FDA-approved medicines available for your medical condition. Propofol-Lipuro 1% injectable emulsion for infusion may pass into breast milk. You should stop breastfeeding and throw away (discard) breast milk for 24 hours after you have received Propofol-Lipuro 1% injectable emulsion for infusion.How do I report side effects with PROPOFOL-LIPURO 1% INJECTABLE EMULSION FOR INFUSION?Tell your healthcare provider right away if you have any side effect that bothers you or does not go away.Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report the problem to the B. Braun Medical Inc. USA by phone at 1-833-425-1464 or by email at productqualityexcellence@bbraunusa.com.HOW CAN I LEARN MORE ABOUT COVID-19?Ask your healthcare providerVisit https://www.cdc.gov/COVID19Contact your local or state public health departmentWHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)?The United States FDA has made Propofol-Lipuro 1% injectable emulsion for infusion available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Service (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.Propofol-Lipuro 1% injectable emulsion for infusion has not undergone the same type of review as an FDA-approved product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, and available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that it is reasonable to believe that the product meets certain criteria for safety, performance, and labeling, and may be effective in treatment of patients during the COVID-19 pandemic. All of those criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic. The EUA for Propofol-Lipuro 1% injectable emulsion for infusion is in effect for the duration of the COVID-19 declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).

* Please review the disclaimer below.